Article Text

Download PDFPDF
Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary
  1. Ying Zhu1,
  2. Fanlong Meng2,
  3. Huibin Fang1,
  4. Zhigang Zhang1,3,
  5. Liang Wang1 and
  6. Wei Zheng1
  1. 1 Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China
  2. 2 Department of Gynecology and Obstetrics, Changxing people's hospital, Huzhou, China
  3. 3 Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China
  1. Correspondence to Professor Wei Zheng, Cancer Institute, Hang Zhou, China; zhengwei{at}zju.edu.cn; Professor Liang Wang; 2196042{at}zju.edu.cn

Abstract

Objective Neuroendocrine tumors are rare in the ovary. Definitive epidemiologic and prognostic information for neuroendocrine carcinoma of the ovary is lacking. This retrospective population-based study aimed to elucidate the demographic and clinicopathologic characteristics of neuroendocrine carcinoma of the ovary.

Methods Patients with neuroendocrine carcinoma of the ovary diagnosed between January 1994 and December 2014were identified from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Cancer-specific survival was calculated by Kaplan-Meier plots and comparisons were performed using the log-rank test. A Cox hazard regression analysis was performed to identify independent predictors of cancer-specific survival in patients with neuroendocrine carcinoma of the ovary.

Results A total of 166 patients were included, and 21.1% were younger than 50 years old. The majority of patients (59.6%) presented with unilateral tumors. Patients with neuroendocrine carcinoma of the ovary had significantly worse survival compared with most subtypes of epithelial ovarian cancer (including serous, endometrioid, mucinous, and clear cell), and similar to ovarian carcinosarcoma. The rate of cancer-specific survival was significantly different under the SEER histologic stages. Patients with low-grade neuroendocrine carcinoma of the ovary had longer average survival times than those with high-grade neuroendocrine carcinoma of the ovary (HR 3.43, 95% CI 1.56 to 7.54, p=0.002). Patients with neuroendocrine carcinoma of the ovary who underwent surgery had significantly better survival than those who did not undergo surgery (HR 2.23; 95% CI 1.45 to 3.43, p=<0.05).

Conclusions Early clinical stage and low tumor grade independently predict better survival in patients with neuroendocrine carcinoma of the ovary. Surgery may be a useful therapy for neuroendocrine carcinoma of the ovary.

  • Neuroendocrine carcinoma of the ovary
  • Epidemiology
  • Cancer specific survival
  • Prognosis
  • SEER
View Full Text

Statistics from Altmetric.com

Footnotes

  • YZ and FM contributed equally.

  • Contributors Study design and manuscript writing: YZ, WZ, LW. Study selection and data analysis: YZ, HF, ZG. Study quality evaluation and revision: HF, WZ, LW. All authors have read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.